# Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation

> **NCT01747499** · PHASE1,PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 54 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
- Precursor Cell Lymphoblastic Leukemia-Lymphoma

## Interventions

- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT01747499
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-04-15
- **Primary completion:** 2018-08-31
- **Final completion:** 2018-12-24
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Enrolling 8 more patients would be statistically unlikely that the primary endpoint would be reached (reduce day 180 grade II-IV GVHD rates to 20% or less)
- **Last updated:** 2019-10-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01747499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01747499, "Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01747499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*